The animal health industry is experiencing rapid growth, driven by increasing pet ownership and rising demand for advanced veterinary treatments. Protein therapeutics, particularly monoclonal antibodies (mAbs), and long-acting biologics (LAIs), are transforming the sector, with blockbuster drugs like lokivetmab (Cytopoint) and frunevetmab (Solensia) paving the way for future innovations. Chronic conditions such as diabetes, arthritis, cancer, and allergic disorders in pets present significant opportunities for novel biologics.

Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) are becoming central to this evolution. With increasing complexity in veterinary formulations, regulatory scrutiny, and production requirements, outsourcing is becoming a preferred strategy for pharmaceutical companies. Large players like Zoetis and Boehringer Ingelheim are already leveraging external partners to enhance manufacturing efficiency.

Leading CRO/CDMO Syngene understands the challenges in developing animal health products, having worked with several global clients like Zoetis, Elanco, etc. We offer research and development services in veterinary medicine, nutrition, hygiene, and care across small molecules and biologics. We have supported numerous clients in developing novel chemical entities and APIs, including successfully undertaking several process scale-up programs.